Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 3
2(28.6%)
7Total
Phase 2(5)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT00086203Phase 2Completed

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

Role: lead

NCT00083239Phase 2Completed

Study of Talabostat in Advanced Melanoma

Role: lead

NCT00083252Phase 2Completed

Study of Talabostat and Cisplatin in Advanced Melanoma

Role: lead

NCT00290017Phase 3Terminated

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Role: lead

NCT00116389Phase 2Terminated

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Role: lead

NCT00243204Phase 3Terminated

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Role: lead

NCT00080080Phase 2Completed

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Role: lead

All 7 trials loaded